TABLE 2.

Initial Triple Combination ARV Therapy, by NRTI Pair and Third Drug; Distribution of Initial Triple Combination ARV Therapy, by Initial Therapy; Distribution of Initial Triple Combination ARV Therapy by Third Drug and Mortality Status

		First regimen
NRTI pair	Overall frequency	Boosted PI (n = 323)	NNRTI (n = 580)	Follow-up* (mo)
AZT/3TC, n (%)	307 (34.0)	75 (23.2)	232 (40.0)	32.3 (22.6–44.0)
d4T/3TC, n (%)	323 (35.8)	138 (42.7)	185 (31.9)	38.2 (26.7–55.3)
ddI/3TC, n (%)	167 (18.5)	18 (5.6)	149 (25.7)	32.7 (21.1–48.1)
Other, n (%)	106 (11.7)	92 (28.5)	14 (2.4)	17.7 (13.8–28.7)
		First regimen
Third drug		Boosted PI (n = 323)	NNRTI (n = 580)	Follow-up† (mo)
Efavirenz, n (%)		—	120 (20.7)	32.5 (20.8–43.8)
Nevirapine, n (%)		—	460 (79.3)	40.6 (27.0–56.4)
Atazanavir + ritonavir, n (%)†		75 (23.2)	—	17.2 (13.5–19.3)
Lopinavir + ritonavir, n (%)†		248 (76.8)	—	28.9 (21.3–36.4)
		Changed regimen to
First regimen		Boosted PI	NNRTI	Nonboosted PI plus NNRTI
Boosted PI, n (%)		285 (31.6)	33 (3.7)	6 (0.7)
NNRTI, n (%)		133 (14.7)	441 (48.8)	7 (0.8)
Regimens		Alive total = 807	Deceased total = 96	P
NNRTI-based regimens		n = 512	n = 68	0.5264
Efavirenz, n (%)		104 (20.3)	16 (23.5)
Nevirapine, n (%)		408 (79.7)	52 (76.5)
Boosted PI–based regimens		n = 295	n = 28	0.1571
Atazanavir + ritonavir, n (%)		72 (24.4)	3 (10.7)
Lopinavir + ritonavir, n (%)		223 (75.6)	25 (89.3)

The numbers of this table do not sum to 903 patients or 100% given that during the follow-up of some individuals, their therapy had been changed to all categories displayed.

ARV, antiretroviral; AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ddI, didanosine.

^*The values are reported in median years and the interquartile range is presented in parenthesis.

^†Protease inhibitors boosted with <200 mg/d ritonavir;